Contracts that tie payment to patient outcomes can be difficult to draft when governing statutes were designed to prevent payments connected to anything other than fair market value for services provided. A quality target does not resolve the issue. A rebate based on how patients fare, or manufacturer funding for adherence support built around its own product, may be viewed as remuneration linked to utilization.
These limits affect manufacturers, health systems, and large payers that negotiate agreements in which payment changes with results. Safe harbors and exceptions, including fraud and abuse waivers in shared savings ACOs, are available, but many were written for arrangements with fixed compensation and defined volume. An outcomes-based contract may not fit those requirements easily, even when the parties intend to reward better care rather than promote unnecessary use.
The anti-kickback statute and utilization-linked payments
The anti-kickback statute prohibits offering remuneration to induce referrals or purchases of items payable by a federal program. That rule presents a drafting problem when an agreement connects payment with both product use and patient outcomes.
For example, a manufacturer might offer a rebate when patients reach an agreed result. The manufacturer might also pay for adherence support built around its own product. Since the payment or service relates to a product that is prescribed, purchased, or used, the arrangement may be viewed as remuneration tied to utilization.
The parties therefore must assess more than the contract’s stated clinical purpose. They also need to consider whether money, services, or discounts could be understood as encouraging referrals or purchases paid for by a federal program, including the concerns addressed in health care fraud enforcement actions. The connection between the financial term and the product may matter even when the contract is intended to improve adherence or outcomes.
This does not mean every outcomes-based arrangement violates the statute. It means a payment formula tied to utilization can make the arrangement more difficult to design. The parties may use narrower terms or more cautious formulas, or decide not to proceed.
A manufacturer may accept lower revenue when outcomes are poor, while a payer may prefer to pay more when outcomes improve. Those goals can fit a value-based contract, but the legal analysis becomes more difficult when the payment formula cannot be separated clearly from product utilization.
Physician relationships add strict liability
The physician self-referral law creates a separate restriction on financial relationships between hospitals and referring physicians. It is a strict liability rule. A technical error in the written arrangement can invalidate it regardless of the parties’ intent.
This issue can arise when a value-based contract includes detailed conditions and several participants. The parties may need to specify the services covered, the compensation, the performance measures, and the conditions that cause payments to change. If the arrangement creates a financial relationship covered by the physician self-referral law, its clinical purpose does not resolve the problem.
The rule affects how health systems organize collaborations with physicians. An agreement intended to improve outcomes may still require careful review of the financial relationship’s form and terms. The relevant question is whether the written agreement fits the applicable exception and avoids a technical defect. A favorable clinical result does not remove that requirement.
Medicaid pricing can extend one concession
The Medicaid drug rebate program creates a different pricing concern. A manufacturer’s lowest price to most purchasers helps set the government’s price. As a result, a large outcomes-based concession to one payer may affect what the manufacturer collects across the program.
That possibility makes targeted contracts harder to price. A manufacturer might give one payer a substantial discount if patients fail to meet an agreed outcome. If the concession is treated as the manufacturer’s lowest price to most purchasers, however, it could affect the manufacturer’s obligations or collections throughout the broader program. The effect could reach beyond the contract that produced the concession.
Manufacturers may therefore hesitate to offer an unusually large concession to one payer. The rule can limit the size or design of an outcomes-based rebate even when the payer wants a direct performance guarantee. The parties must account for the economics of their agreement and how it may interact with the Medicaid rebate program.
What these limits mean for buyers
These rules mainly shape negotiations among manufacturers, health systems, and large payers. They do not determine what a retail buyer pays outside insurance. Someone purchasing weight-loss medication without insurance is outside that system and faces list or clinic pricing. Modern medication costs can vary across those pricing sources, as this GLP-1 cost guide shows.
A payer may negotiate a rebate based on outcomes, but that arrangement does not automatically become a discount for an uninsured purchaser. The contract may apply only to a federal program, a particular health system, or a defined group of patients covered by the agreement. Terms negotiated within that system do not establish the price available to a retail buyer.
These rules can make it harder to create contracts that move risk from payers to manufacturers or pay for results instead of volume, as discussed in payment for outcomes instead of visits. They do not create one retail price. The anti-kickback statute addresses remuneration connected to referrals or purchases. The physician self-referral law can invalidate a technically defective financial relationship. The Medicaid rebate program can extend the pricing effect of one concession. Those limits help explain why a value-based contract can make economic sense and still be difficult to put into practice.